SEC Comment Letter 0000000000-24-014309 to Processa Pharmaceuticals, Inc. (PCSA)
Processa Pharmaceuticals, Inc.
Date: Dec. 30, 2024 · CIK: 0001533743 · Accession: 0000000000-24-014309
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283986
Letter
December 28, 2024 George Ng Chief Executive Officer Processa Pharmaceuticals, Inc. 7380 Coca Cola Drive, Suite 106 Hanover, Maryland 21076 Re:Processa Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed December 20, 2024 File No. 333-283986 Dear George Ng: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Neda Sharifi
Show Raw Text
December 28, 2024
George Ng
Chief Executive Officer
Processa Pharmaceuticals, Inc.
7380 Coca Cola Drive, Suite 106
Hanover, Maryland 21076
Re:Processa Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed December 20, 2024
File No. 333-283986
Dear George Ng:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Neda Sharifi